Results 11 to 20 of about 9,543,544 (289)
Epidemiology, management and outcomes of Graves’ disease—real life data [PDF]
Endocrine, 2017 PurposeTreatment options in Graves’ disease are clearly defined, but management practices and the perceptions of success are varied. The outcomes of treatment in large consecutive cohorts of Graves’ disease have not been well characterised.
Y. Hussain +3 more
semanticscholar +3 more sources
Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis [PDF]
, 2021 Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis.
Cardoso, Helena +3 more
core +1 more source
Isolation and characterisation of graves’ disease-specific extracellular vesicles from tissue maintained on a bespoke microfluidic device [PDF]
, 2021 This report demonstrates the ability of a microfluidic device to maintain human Graves' disease tissue enabling the isolation and characterisation of Graves' disease specific exosomes.
England, James +4 more
core +1 more source
Graves-Basedow disease and potential risk factors [PDF]
Vojnosanitetski Pregled, 2008 Background/Aim. Graves-Basedow disease is a common multifactorial genetic syndrome, which is determined by several genes and environmental factors. The aim of the present study was to investigate the presence of risk factors for developing Graves-Basedow
Živanović Dušica +3 more
doaj +1 more source
Graves’ disease and Graves’ orbitopathy following COVID-19
Journal of Endocrinological Investigation, 2021 Upon genetic predisposition, Graves’ disease (GD) is believed to be triggered by nongenetic factors, including infections [1]. The immune system plays a role in Coronavirus disease 2019 (COVID-19), being involved in its clinical course and outcome [2 ...
G. Lanzolla, C. Marcocci, M. Marinò
semanticscholar +1 more source
European Journal of Case Reports in Internal Medicine, 2021 Graves' disease is the most frequent cause of hyperthyroidism in young women. This auto-immune disease is due to the production of class 1 IgG stimulating the TSH receptor.
Guillaume Pierman +2 more
semanticscholar +1 more source
Journal of Endocrinological Investigation, 2020 To the Editor Since the outbreak of the SARS-CoV-2 pandemic, there have been many reports of autoimmune diseases triggered by or related to COVID-19 such as Guillain–Barre’s syndrome, autoimmune haemolytic anaemia, autoimmune thrombotic thrombocytopenic ...
M. Mateu-Salat, E. Urgell, A. Chico
semanticscholar +1 more source
A Mathematical Model of Thyroid Disease Response to Radiotherapy [PDF]
Mathematics 2021, 9(19), 2365, 2021 We present a mechanistic biomathematical model of molecular radiotherapy of thyroid disease. The general model consists of a set of differential equations describing the dynamics of different populations of thyroid cells with varying degrees of damage caused by radiotherapy (undamaged cells, sub-lethally damaged cells, doomed cells, and dead cells), as
arxiv +1 more source
Archives of Endocrinology and Metabolism, 2020 Objective Graves’ disease (GD) is the main cause of hyperthyroidism among adults. It is an autoimmune condition classically marked by the Merserburg Triad (goiter, thyrotoxicosis, and orbitopathy), but the change in presentation of GD over time has ...
Wanesa Pinto +4 more
doaj +1 more source
Minimal change disease associated with Graves’ disease and methimazole use
Revista Colombiana de Nefrología, 2022 Introduction. Graves' disease causes kidney injury through multiple mechanisms, including the treatment for this condition. Nephrotic syndrome due to minimal change disease (MCD) is an unusual form of such kidney injury; the association between ...
Andrés Fernando Rodríguez-Gutiérrez +1 more
doaj +1 more source